Arh. farm. 2022; 72: 674 – 688
Original scientific paper/Originalni naučni rad
Digital light processing (DLP) 3D printing
technique applied in the fabrication of two-layered
tablets: the concept of a combined polypill
Ivana Adamov1*, Djorđe Medarević1, Branka Ivković2,
Aleksandar Ivković3, Svetlana Ibrić1
1
University of Belgrade – Faculty of Pharmacy, Department of Pharmaceutical
Technology and Cosmetology, Vojvode Stepe 450, 11221 Belgrade, Serbia
2
University of Belgrade – Faculty of Pharmacy, Department of Pharmaceutical
Chemistry, Vojvode Stepe 450, 11221 Belgrade, Serbia
3
Academy of Applied Technical Studies, Katarine Ambrozić 3, 11000 Belgrade, Serbia
*Corresponding author: Ivana Adamov, E-mail: ivana.adamov@pharmacy.bg.ac.rs
Abstract
Ever since 3D printing was introduced to the field of pharmacy, it has caused a paradigm
shift from the manufacturing of large-scale to small batches of medicines tailored accordingly to
the specific needs of patients. This study aimed to formulate and fabricate two-layered 3D tablets
using the digital light processing (DLP) technique. Hydrochlorothiazide (HHT,5%,w/w) and
warfarin sodium (WS,5%,w/w) were selected as model drugs. The printing process was initiated
with 0.1% of photoinitiator, at a constant ratio of poly(ethylene glycol)diacrylate and
poly(ethylene glycol) 400, 1:1, with the addition of water (10%,w/w). Single-layered tablets of
8.00 mm diameter and 1.50 mm thickness, containing HHT and WS respectively, were
successfully printed, as well as combined two-layered 3D tablets, with each of the active
substances in separate layers. Dissolution tests of single-layered tablets showed immediate, but
incomplete release of WS (81.47±1.47%, after 45min), and prolonged and complete release of
HHT (98.17±3.11%, after 8h), while significantly slower and incomplete release of both drugs
from the combined two-layered 3D tablets was observed. The absence of drug-polymer
interaction and presence of a layered cross-sectional tablet structure were confirmed. DLP
technique enables simple and rapid fabrication of combined two-layered 3D tablets, while further
optimization of formulation factors is necessary to achieve complete drug release.
Key words: DLP technique, hydrochlorothiazide, warfarin sodium,
combined two-layered 3D tablets, personalized medicine
https://doi.org/10.5937/arhfarm72-40365
674
Introduction
Three-dimensional (3D) printing as an additive manufacturing technology has the
potential to revolutionize the field of manufacturing by transforming 3D models into
reality based on a successive layering mechanism (1, 2). Since its introduction in the drug
manufacturing field, 3D printing has captured the attention of the scientific and
professional public, contributing to the progressive research of this technology and its
potential applicability in the pharmaceutical field, opening the door to completely new
approaches, not only in the way drugs are created, used and produced, but also with strong
tendencies to make personalized medicine more realistic and approachable (3, 4).
The American Society for Testing and Materials (ASTM) International has
classified 3DP technologies into seven main categories: vat polymerization, binder
jetting, material jetting, powder bed fusion, extrusion of material, directed energy
deposition, and sheet lamination (5). Amid the mentioned technologies, vat
photopolymerization provides 3D objects of high resolution without operating with high
temperature ranges, which makes it suitable for thermosensitive drugs (2). The focus of
this study was on a vat polymerization technique known as digital light processing (DLP)
3D printing. In this technique, a digital micromirror is used to gradually expose and
solidify an entire layer of liquid photopolymer solution following a layer-by-layer
mechanism. (6, 7). After each successive layer is printed, the build platform is immersed
in a tank filled with photopolymer solution, ensuring that each successive layer is cured
by the light source and adheres to the previous one, until the process of printing the object
is complete. (8). Based on the fact that the layers are formed due to light irradiation, one
of the main drawbacks limiting the application of this technique is photosensitivity of the
drugs, as well as the confined number of available photocrosslinkable polymers (6, 9). So
far, reported studies have confirmed the potential of the DLP technique to provide
innovative, non-conventional drug dosage forms (10, 11), as well as small batches of
tablets with desirable drug release profiles and flexibile dosing regimens (8, 12), creating
an opportunity for the pharmaceutical industry to switch from a “one size fits all”
approach to the fabrication of patient-tailored drugs (4, 8, 13).
Over the past few years, researchers have put a lot of effort into developing a new
platform that could enable flexible dosing regimens and dosage forms with different drug
combinations (14). It has been recognized that 3D printing technologies have the potential
to individualize drug therapy by combining multiple drugs into a single dosage form or
polypill in a wide variety of shapes, sizes, geometries and other customized features (14,
15). A recently conducted pilot study has shown that the concept of a combined polypill
could reduce patient pill burden, which in turn could lead to improved patient adherence
and therapeutic outcomes (16). Compared to convetional tablets with fixed drug
combinations, which typically contain fixed strengths on a large commercial scale and
are therefore unsuitable for therapies that require flexible dose adjustments or drug
combination(s), 3D printed tablets combine multiple active substances into a single
dosage form with different geometric shapes, and due to the physical separation of the
675
drugs, it is possible to achieve tunable doses and release profiles for each drug
individually, as well as to co-formulate potentially incompatible drugs (14, 17, 18).
To the best of our knowledge, the potential of the DLP 3D printing technique in the
manufacturing of polypills has not yet been reported in the literature; therefore, this study
aimed to formulate and fabricate two-layered 3D tablets that combine two different drugs,
hydrochlorothiazide (HHT) and warfarin sodium (WS) into a single 3D tablet, in order to
investigate the pertinence of the DLP 3D printing technique to the concept of a combined
polypill. HHT and WS have been chosen as drug candidates due to their common
administration in the therapy of cardiovascular diseases (CVD) (19). Moreover, WS
belongs to the class of drugs that require dose titration due to its narrow therapeutic index
(19), which makes it an ideal candidate for the individualization of therapy.
Experimental part
Materials
Poly (ethylene glycol) diacrylate (PEGDA, average MW 700) was obtained from
Sigma-Aldrich, Tokyo, Japan. Poly (ethylene glycol) (PEG 400, average MW 400) was
purchased from Fagron B.V., Rotterdam, The Netherlands. Hydrochlorothiazide (HHT,
MW 297.7) and warfarin sodium (WS, MW 330.3) were kindly donated by Galenika AD,
Belgrade, Serbia. Diphenyl (2,4,6-trimethylbenzoyl) phosphine oxide (DPPO) was
obtained from Sigma-Aldrich, Steinheim, Germany.
Methods
Preparation of Photopolymer Solutions
HHT and WS were chosen as model drug substances commonly used together in
the treatment of CVD. PEGDA was used as a photopolymerizing monomer, which in the
presence of a low amount photoinitiator (DPPO) forms a polymeric matrix of printed
tablets. PEG 400 was added to improve drug release and as a co-solvent for the drugs.
Purified water was used as a vehicle for drug substances.
Two formulations of the same quantitative composition were prepared (Table I).
PEGDA and PEG 400 were maintained at a constant 1:1 (w/w) ratio, with the addition of
10% (w/w) of water. HHT or WS was then added to the solution at a concentration of 5%
(w/w), while DPPO (0.1%, w/w) was added at the very end. The solution was thoroughly
mixed until complete dissolution of the drug was achieved, and transferred into the
printer.
676
Table I
Tabela I
Composition (%, w/w) of photopolymer solutions
Sastav (%, m/m) fotopolimernih rastvora
Formulation
Substance
HHT
WS
PEGDA
PEG 400
DPPO
Water
CF
F1
F2
5.00
42.45
42.45
0.10
10.00
5.00
42.45
42.45
0.10
10.00
3D Printing of Tablets
A cylindrical-shape 3D model of tablets, with a diameter of 8.00 mm and thickness
of 1.50 mm, was created in the Autodesk fusion software version 2.0.8809 (Autodesk Inc,
San Rafael, CA, USA) and exported as a stereolithography file (.stl) into the 3D printer
software (Chitubox, version 1.7.0). A Wanhao Duplicator 8 printer (Wanhao, Zhejiang,
China) equipped with a 405 nm UV lamp was used for tablet printing. First, 3D tablets
were printed from individual formulations – HHT tablets, formulation F1 and WS tablets,
formulation F2 (hereinafter referred to as single-layered tablets), while combined twolayered 3D tablets were fabricated from both formulations separately, in a two-step
printing process. The single-layered WS tablet was printed on the top of the previously
printed single-layered HHT tablet, using the same 3D printing file. Formulation F1, in the
resin tank, was easily replaced by formulation F2, the build platform was restored to its
previous position and the printing process restarted.
Preliminary experiments were carried out in order to optimize the process and
establish printing parameters that enabled fast and effective fabrication of 3D tablets.
Based on these results, all tablets were printed with the parameters shown in Table II.
Table II Parameters of printing process
Tabela II Parametri procesa štampanja
Parameter
Value
Layer height
Bottom layer count
Exposure time
Bottom exposure time
Bottom lift distance
Lifting distance
Bottom lift speed
Lifting speed
Retract speed
0.1 mm
5
40 s
40 s
5 mm
5 mm
60 mm/min
60 mm/min
150 mm/min
677
Mass and Dimension Variation
After being removed from the build platform, the printed tablets were washed with
2-propanol and wiped with a tissue to eliminate uncured liquid from the surface. 3D
tablets were then weighed on an analytical balance (Kern & Sohn, Germany) and
measured (length/diameter and thickness) using a digital caliper (Vogel Germany GmbH
& Co. KG, Kevelaer, Germany). Measurements were performed on 10 tablets.
Determination of Drug Content
UV/VIS spectrophotometry (Evolution 300, Thermo Fisher Scientific, Waltham,
MA, USA) was used to determine the drug content, at a wavelength of 273 nm
(corresponding to the highest molar absorbance of HHT) and 307 nm (corresponding to
the highest molar absorbance of WS). For standard preparation, 10 mg of HHT or WS
was dissolved in 10 mL of absolute ethanol, shaken in an ultrasonic bath BandelinSonorex RK102H (Sonorex-Bandelin, Berlin, Germany) for 15 min at room temperature,
cooled and then filtered through 0.45 µm filters (Millipore, Bedford, MA, USA).
Adequate dilution of the prepared standard solutions in distilled water was provided. For
determination of drug loading in the combined two-layered 3D tablets, single drug-loaded
layers (i.e., single-layered tablets) were crushed (n = 3), according to the methodology of
Xu et al. (2020). The mass of each sample equivalent to an average mass of a singlelayered tablet was weighed and dissolved in a volumetric flask with 10 mL of absolute
ethanol and shaken in an ultrasonic bath for 15 min. Samples then underwent the same
procedure as described for standard preparation. The analysis was performed in triplicate,
while the obtained drug content was calculated as a percentage of the theoretical drug
content with standard deviation (SD).
In Vitro Drug Release Testing
Dissolution profiles were obtained using a mini-paddle USP-II Erweka DT 600
(Erweka, Langen, Germany) apparatus. 3D tablets (n = 2) were placed in 250 mL of
distilled water for 8 h. The rotation speed of the paddles was set to 50 rpm, and the tests
were carried out at 37 ± 0.5 °C. Aliquots (4 mL) were withdrawn at time intervals of 15,
30, 45, 60, 120, 180, 240, 300, 360, 420 and 480 minutes, and immediately replaced with
the same amount of fresh medium. All samples were filtered through 0.45 µm filters, and
the released amounts of HHT and WS were determined by HPLC method using a Dionex
Ultimate 3000 (Thermo Scientific, USA) HPLC system. Analyses were conducted under
the following experimental conditions: C18 column (250 × 4.6 mm, 5 μm), mobile phase
consisting of 50:50 (v/v) mixture of 0.1% (v/v) phosphoric acid in water and acetonitrile,
at a flow rate of 1.2 ml/min, an injection volume of 20 μl, a detection wavelength of 215
nm, and a column temperature of 30 °C. All experiments were performed in duplicate.
Differential Scanning Calorimetry (DSC)
DSC was carried out on a DSC 1 instrument (Mettler Toledo, Giessen, Germany).
Pure active substances and pulverized single-layered tablets were precisely weighed (5–
678
7 mg), placed in aluminum pans and subjected to heating at 10 °C/min in the range from
0 to 250 °C (WS) and 0 to 350 °C (HHT), under constant nitrogen gas flow of 50 mL/min.
An empty aluminum pan was used as a reference. STARe software (version 12.10,
Mettler, Toledo) was used to analyze the acquired data. DSC analysis was conducted to
investigate the physical properties of HHT and WS within the printed 3D tablets.
Polarized light microscopy
The internal structure of both single-layered and combined two-layered 3D tablets,
before and after dissolution testing, was visually examined by an Olympus BX53-P
polarized microscope (Olympus, Tokyo, Japan) with UPLFLN4XP and UPLFLN10XP
objectives. Images were taken by the cellSens Entry Version 1.14 software (Olympus,
Tokyo, Japan).
Fourier-Transform Infrared Spectroscopy (FTIR)
The assessment of potential drug-polymer interactions was performed by FTIR
spectroscopy. Analyses of thoroughly pulverized single-layered 3D tablets and pure
materials, as references, were conducted with a Nicolet iS10 (Thermo
Scientific,Waltham, MA, USA) FTIR spectrometer, equipped with a single reflection
ATR system (Smart iTR, Thermo Scientific, Waltham, MA, USA) with a diamond plate
and ZnSe lens. The spectra were recorded from 4 000 to 650 cm–1, using a resolution of
2 cm–1.
Results and Discussion
Cylindrical single-layered and combined two-layered 3D tablets of constant
diameter and thickness were successfully printed with a DLP 3D printer (Figure 1). In
about 10 minutes, 15 objects were printed at once, confirming the fact that the DLP 3D
printing technique offers a simple and fast way to produce small batches of tablets at room
temperature (8, 10, 12, 20). 3D tablets with a fine surface and the same color as the initial
photopolymer solution were obtained (Figure 1).
The measured weight, diameter and thickness of 3D tablets are shown in Table III.
All tablets were uniform in dimensions, while the combined two-layered 3D tablets
showed the greatest variations in dimensions and mass. Such results may be explained by
the fact that the printing process was conducted in two steps, meaning that the previously
printed layer of HHT tablets was used as a bottom base for the layer of WS tablets, which
might have caused additional solidification around the initially created 3D model and
resulted in the expansion of the diameter. Robles-Martinez et al. (2019) reported similar
results, where multi-layered cylindrical polypills containing six-different drugs obtained
by the vat photopolymerization 3D printing technique showed greater variations in real
dimensions compared to the targeted ones (14). The percentage of obtained drug content
in single-layered HHT tablets was lower (82.63 ± 0.19) compared to drug content in
single-layered WS tablets (107.32 ± 0.53). As for the drug content in HHT, similar results
were published by Xu et al. (2020), where the lower drug loading in 3D tablets than that
679
in the photopolymer solution occurred due to incomplete drug extraction from the crosslinked polymeric matrix (9).
Figure 1. Cylindrical 3D model of tablets created in Autodesk fusion software and
printed single-layered (A) WS tablets, formulation F2 and (B) HHT tablets,
formulation F1 and (C) combined two-layered 3D tablets, formulation CF
Slika 1.
Cilindrični 3D model tableta kreiran u Autodesk fusion programu i
odštampane jednoslojne (A) WS tablete, formulacija F2 i (B) HHT tablete,
formulacija F1 i (C) kombinovane dvoslojne 3D tablete, formulacija CF
Table III Measured weight, diameter and thickness of 3D tablets (mean ± SD)
Tabela III Masa, prečnik i debljina 3D tableta (srednja vrednost ± SD)
Formulation
F1
F2
CF
Weight (mg)
100.96 ± 5.93
92.54 ± 3.61
186.89 ± 12.06
Diameter (mm)
9.15 ± 0.39
8.74 ± 0.21
10.01 ± 0.46
Thickness (mm)
1.32 ± 0.04
1.37 ± 0.05
2.06 ± 0.16
After the dissolution test, the 3D tablets remained intact, showing no signs of
erosion or disintegration, which is consistent with the previously reported results (8, 10,
11). Dissolution profiles for single-layered and combined two-layered 3D tablets are
shown in Figure 2.
680
Figure 2. Dissolution profiles of fabricated single-layered (F1 and F2) and combined
two-layered (CF1 and CF2) 3D tablets
Slika 2.
Profili brzine rastvaranja lekovite supstance iz jednoslojnih (F1 i F2) i
kombinovanih dvoslojnih (CF1 i CF2) 3D tableta
According to Chapter 5.17.1, Recommendation on dissolution testing, in the
European Pharmacopoeia Edition 10.2, the acceptance criteria at level S1, for
conventional-release dosage forms, are that at least 80% of the active substance is
released within a specified time, typically 45 min or less, while for prolonged-release
dosage forms the acceptance criteria are usually expected to consist of three time points
or more. The 1st specification point corresponds to a dissolved amount typically of 20%
to 30 % of drug, the 2nd specification point corresponds to around 50% of dissolved drug,
and the final specification point is intended to ensure almost complete release, more than
80% of drug. According to the acceptance criteria, single-layered WS tablets (F2) showed
immediate release – more than 80% of WS was released within 45 min, while singlelayered HHT tablets (F1) showed prolonged drug release – approximately 20% to 30%
of the drug was released after 30 minutes, about 50% of the drug between the first and
second hour, and a plateau was achieved after five hours (Figure 1). The differences in
drug dissolution rates between HHT and WS may be attributed to their aqueous
solubilities: 0.70 mg/mL for HHT (21), and more than 7 g/mL for WS (22). WS was
rapidly dissolved from the outer layers of the tablet, based on its high-water solubility,
while about 13% of the drug was captured inside the inner layers of the tablet and caused
incomplete release of WS. Studies have shown that formulation and geometrical factors,
such as PEGDA/PEG ratio and surface area to volume ratio (SA/V), also affect drug
dissolution rate from polymeric matrix (6, 11). Compared to single-layered tablets,
combined two-layered 3D tablets showed significantly slower drug release, which may
681
be explained by the fact that in combined two-layered 3D tablets the surface area between
the two attached tablets was blocked and therefore unavailable for drug dissolution.
Consequently, the SA/V ratio was decreased, which affected the dissolution rates of both
drugs from the combined two-layered 3D tablets (CF1 and CF2). Further research on
increasing the drug dissolution rate from combined two-layered 3D tablets is necessary,
and formulation strategies that promote higher drug release, such as increasing PEG 400
or water concentration, should be considered (6, 11).
DSC analysis was conducted to determine whether the drug was suspended or
dissolved within the polymeric matrix. DSC thermograms of pure drug substances and
formulations are presented in Figure 3. The DSC thermogram of pure HHT (Figure 3a)
showed an endothermic peak at 271.6 °C, corresponding to its melting point, and another
exothermic one, with a peak temperature of 311.5 °C, related to its degradation (23). A
typical DSC spectrum of WS in amorphous form is shown in Figure 3b. A broad
endotherm at around 100 °C, corresponding to the moisture loss, and a small endotherm
peak at approximately 160–165 °C, representing the glass transition temperature of
amorphous WS, were observed (24). The absence of typical HHT or WS peaks in the
thermograms of the pulverized single-layered tablets (F1 or F2) indicates that the HHT
or WS were dispersed in an amorphous form or dissolved in the polymer. However, the
dissolution of drug crystals due to the high temperatures reached during DSC analysis
cannot be neglected, and therefore polarized light microscopy was further performed.
Figure 3. DSC thermograms of: (a) pure HHT and formulation F1 and (b) pure WS
and formulation F2
Slika 3.
DSC termogrami: (a) čistog HHT i formulacije F1 i (b) čistog WS i
formulacije F2
Cross-sections of printed tablets, before and after the dissolution test, obtained by
polarized-light microscope are presented in Figure 4. Crystals of the drugs were not found
in the cross-sections of both single-layered (F1 and F2) and combined two-layered (CF)
682
tablets indicating that the drug did not crystallize in the photoreactive solution during the
process of 3D printing (12). Parallel layers were observed in all printed tablets, both
before and after the dissolution test, confirming the fact that the tablets were obtained in
a layer-by-layer manner, and without signs of disintegration after the dissolution test. In
Figure 4c, the difference between the two separate tablets (single-layered WS and singlelayered HHT tablet) attached to each other can be clearly distinguished. In all
formulations, after the dissolution test, longitudinal channels caused by drug diffusion
from the polymeric matrix were observed, which is in accordance with the obtained drug
release results.
Figure 4. Cross-sections of tablets before (above) and after (below) dissolution testing,
respectively: (a) F1; (b) F2; (c) CF
Slika 4.
Poprečni preseci tableta pre (iznad) i nakon (ispod) ispitivanja brzine
rastvaranja lekovite supstance, redom: (a) F1; (b) F2; (c) CF
An unexpected photopolymer-drug reaction has been reported in the literature,
emphasizing that compatibility between drug and photoreactive monomer should be
carefully considered and investigated (9). Accordingly, to confirm that no interactions
between drugs and polymers had occurred, FTIR analysis was conducted, and the FTIR
spectra of PEGDA, PEG 400, HHT, WS and pulverized tablets (F1 and F2) are presented
in Figure 5. PEG 400 showed characteristic peaks at 3445 cm-1 (O-H stretching), 2866
cm-1 (C-H stretching) and 1096 cm-1 (C-O-C ether stretching) (25), all of which can be
distinguished in the spectra of the printed tablets, as well. PEGDA exhibited characteristic
peaks at 2866 cm-1 (CH3 stretching), 1721 cm-1 (C=O stretching) and 1636 cm-1 (acrylate
C=C stretching) (10, 26). The C=C bonds were converted to C-C bonds as a result of the
photopolymerization reaction, and therefore the acrylate bond peaks at 1636 cm-1 in the
683
spectra of the printed tablets were absent (25). The spectrum of pure HHT showed a band
in the region of 1602 cm-1, which corresponds to overlapping absorption bands associated
with deformations of C–C bonds and C=C bonds of the aromatic ring, while those at
1334, 1319 and 1165 cm-1 were related to the SO2 group of sulfonamides, and the one at
1123 cm-1 was related to the SO2 heterocyclic ring (23). All the characteristic peaks of
HHT were identified in the spectrum of the powdered tablets (F1), except those at 1165
and 1123 cm-1, which were overlapped by the dominant broad C-O-C ether band of PEG
400. A large band at 1701 cm-1 corresponds to the stretching vibrations of the two C=O
bonds of WS, while the bands at 1597 cm-1 and 1506 cm-1 correspond to C=C stretching.
The out-of-plane bending vibrations of C–H of the phenyl rings were observed at 899,
756 and 700 cm-1 (27). All the bands were found in the spectrum of the powdered tablets
(F2), confirming that interactions between drugs and polymers did not occur during the
process of 3D printing.
Figure 5. FTIR spectra of PEG 400, PEGDA, HHT, WS and pulverized tablets
(F1 and F2)
Slika 5.
FTIR spektri PEG 400, PEGDA, HHT, WS i sprašenih tableta (F1 i F2)
684
Conclusion
For the first time, a commercial DLP 3D printer has been used to manufacture small
batches of combined two-layered polypills, tablets containing different drugs physically
separated into a single dosage form, disclosing the potential of the DLP 3D printing
technique to be exploited in the field of personalized medicine. The obtained results
confirm the amenability of this innovative technology in the fabrication of combined
medicines in a simple and fast way, which implies that it could also be a suitable
promising tool for decentralized pharmaceutical manufacturing. Although the drug
formulations were printable, further research and optimization of the formulation factors
are needed in light of achieving complete release of HHT and WS drugs from the
polymeric matrix and precise geometry according to the developed 3D model.
Acknowledgement
This study was financed by the Ministry of Education, Science and Technological
Development, Republic of Serbia, through the Grant Agreement with the University of
Belgrade – Faculty of Pharmacy [No: 451-03-68/2022-14/200161].
References
1.
Awad A, Fina F, Trenfield SJ, Patel P, Goyanes A, Gaisford S, et al. 3D printed pellets
(Miniprintlets): A novel, multi-drug, controlled release platform technology. Pharmaceutics.
2019;11(4):148. doi: 10.3390/pharmaceutics11040148.
2.
Rodríguez-Pombo L, Xu X, Seijo-Rabina A, Ong JJ, Alvarez-Lorenzo C, Rial C, et al. Volumetric
3D printing for rapid production of medicines. Addit Manuf. 2022;52:102673. doi:
10.1016/j.addma.2022.102673.
3.
Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D Printing Pharmaceuticals: Drug
Development
to
Frontline
Care.
Trends
Pharmacol
Sci.
2018;39(5):440–451.
doi:
10.1016/j.tips.2018.02.006.
4.
Vaz VM, Kumar L. 3D Printing as a Promising Tool in Personalized Medicine. AAPS
PharmSciTech. 2021;22(1). doi: 10.1208/s12249-020-01905-8.
5.
Alexander AE, Wake N, Chepelev L, Brantner P, Ryan J, Wang KC. A guideline for 3D printing
terminology in biomedical research utilizing ISO/ASTM standards. 3D Print Med. 2021;7(8). doi:
10.1186/s41205-021-00098-5.
6.
Wang J, Goyanes A, Gaisford S, Basit AW. Stereolithographic (SLA) 3D printing of oral modified-
7.
Patel DK, Sakhaei AH, Layani M, Zhang B, Ge Q, Magdassi S. Highly Stretchable and UV Curable
release dosage forms. Int J Pharm. 2016;503(1–2):207–212. doi: 10.1016/j.ijpharm.2016.03.016.
Elastomers for Digital Light Processing Based 3D Printing. Adv Mater. 2017; 29(15). doi:
10.1002/adma.201606000.
685
8.
Stanojević G, Medarević D, Adamov I, Pešić N, Kovačević J, Ibrić S. Tailoring Atomoxetine Release
Rate from DLP 3D-Printed Tablets Using Artificial Neural Networks: Influence of Tablet Thickness
and Drug Loading. Molecules. 2020;26(1):111. doi: 10.3390/molecules26010111.
9.
Xu X, Robles-Martinez P, Madla CM, Joubert F, Goyanes A, Basit AW, et al. Stereolithography
(SLA) 3D printing of an antihypertensive polyprintlet: Case study of an unexpected photopolymerdrug reaction. Addit Manuf. 2020;33:101071. doi: 10.1016/j.addma.2020.101071.
10.
Kadry H, Wadnap S, Xu C, Ahsan F. Digital light processing (DLP) 3D-printing technology and
photoreactive polymers in fabrication of modified-release tablets. Eur J Pharm Sci. 2019;135:60–67.
doi: 10.1016/j.ejps.2019.05.008.
11.
Adamov I, Stanojević G, Medarević D, Ivković B, Kočović D, Mirković D, et al. Formulation and
characterization of immediate-release oral dosage forms with zolpidem tartrate fabricated by digital
light
processing
(DLP)
3D
printing
technique.
2022;624:122046.
doi:
10.1016/j.ijpharm.2022.122046.
12.
Krkobabić M, Medarević D, Cvijić S, Grujić B, Ibrić S. Hydrophilic excipients in digital light
processing (DLP) printing of sustained release tablets: Impact on internal structure and drug
dissolution rate. Int J Pharm. 2019;572:118790. doi: 10.1016/j.ijpharm.2019.118790.
13.
Wang J, Zhang Y, Aghda NH, Pillai AR, Thakkar R, Nokhodchi A, et al. Emerging 3D printing
technologies for drug delivery devices: Current status and future perspective. Adv Drug Deliv Rev.
2021;174:294–316. doi: 10.1016/j.addr.2021.04.019.
14.
Robles-Martinez P, Xu X, Trenfield SJ, Awad A, Goyanes A, Telford R, et al. 3D printing of a multilayered polypill containing six drugs using a novel stereolithographic method. Pharmaceutics.
2019;11(6):274. doi: 10.3390/pharmaceutics11060274.
15.
Jie Y, Tan N, Pong W, Singh J, Khanolkar J, Yao X. On-demand fully customizable drug tablets via
3D printing technology for personalized medicine. J Control Release. 2020;322:42–52. doi:
10.1016/j.jconrel.2020.02.046.
16.
Goh O, Goh WJ, Lim SH, Hoo GS, Liew R, Ng TM. Preferences of Healthcare Professionals on 3DPrinted
Tablets:
A
Pilot
Study.
Pharmaceutics.
2022;14(7):1521.
doi:
10.3390/pharmaceutics14071521.
17.
Alayoubi A, Zidan A, Asfari S, Ashraf M, Sau L, Kopcha M. Mechanistic understanding of the
performance of personalized 3D-printed cardiovascular polypills: A case study of patient-centered
therapy. Int J Pharm. 2022;617:121599. doi: 10.1016/j.ijpharm.2022.121599.
18.
Pereira BC, Isreb A, Isreb M, Forbes RT, Oga EF, Alhnan MA. Additive Manufacturing of a Pointof-Care “Polypill:” Fabrication of Concept Capsules of Complex Geometry with Bespoke Release
against Cardiovascular Disease. Adv Healthc Mater. 2020;9(13). doi: 10.1002/adhm.202000236.
19.
Edwards HD, Webb RD, Conway SE. Effect of oral diuretics on chronic warfarin therapy: A
retrospective
study.
Expert
Opin
Drug
Saf.
2012;11(3):375–380.
doi:
10.1517/14740338.2012.624091.
20.
Krkobabić M, Medarević D, Pešić N, Vasiljević D, Ivković B, Ibrić S. Digital light processing (DLP)
3D printing of atomoxetine hydrochloride tablets using photoreactive suspensions. Pharmaceutics.
2020;12(9):833. doi: 10.3390/pharmaceutics12090833.
686
21.
Khan A, Iqbal Z, Shah Y, Ahmad L, Ullah Z, Ullah A. Enhancement of dissolution rate of class II
drugs (Hydrochlorothiazide); a comparative study of the two novel approaches; solid dispersion and
liqui-solid techniques. Saudi Pharm J. 2015;23(6):650–657. doi: 10.1016/j.jsps.2015.01.025.
22.
Anderson ME, Delmarre D, Gao D, El-Khateeb MA, Centeno C-JS, Pathak SR, inventors; Morton
Grove Pharmaceuticals, Inc., assignee. Stable warfarin sodium liquid formulation and method of
making same. World patent WO 2006/138534 A2. 2006 December 28.
23.
de Souza CMP, dos Santos JAB, do Nascimento AL, Chaves Júnior JV, de Lima Ramos Júnior FJ,
de Lima Neto SA, et al. Thermal analysis study of solid dispersions hydrochlorothiazide. J Therm
Anal Calorim. 2018;131(1):681–689. doi: 10.1007/s10973-017-6091-0.
24.
Dimitrokalli E, Fertaki S, Lykouras M, Kokkinos P, Orkoula M, Kontoyannis C. Warfarin Sodium
Stability in Oral Formulations. Molecules. 2021;26(21):6631. doi: 10.3390/molecules26216631.
25.
Banerjee A, Blasiak B, Pasquier E, Tomanek B, Trudel S. Synthesis, characterization, and evaluation
of PEGylated first-row transition metal ferrite nanoparticles as: T 2 contrast agents for high-field
MRI. RSC Adv. 2017;7(61):38125–38134. doi: 10.1039/C7RA05495E.
26.
Clark EA, Alexander MR, Irvine DJ, Roberts CJ, Wallace MJ, Sharpe S, et al. 3D printing of tablets
using
inkjet
with
UV
photoinitiation.
Int
J
Pharm.
2017;529(1–2):523–530.
doi:
10.1016/j.ijpharm.2017.06.085.
27.
Leopold LF, Ruginǎ D, Oprea I, Diaconeasa Z, Leopold N, Suciu M, et al. Warfarin-capped gold
nanoparticles: Synthesis, cytotoxicity, and cellular uptake. Molecules. 2019;24(22):4145. doi:
10.3390/molecules24224145.
687
3D tehnika digitalne obrade svetlosti (DLP)
primenjena u izradi dvoslojnih tableta: koncept
kombinovane polipilule
Ivana Adamov1*, Đorđe Medarević1, Branka Ivković2,
Aleksandar Ivković3, Svetlana Ibrić1
1
Univerzitet u Beogradu – Farmaceutski fakultet, Katedra za farmaceutsku tehnologiju i
kozmetologiju, Vojvode Stepe 450, 11221 Beograd, Srbija
2
Univerzitet u Beogradu – Farmaceutski fakultet, Katedra za farmaceutsku hemiju,
Vojvode Stepe 450, 11221 Beograd, Srbija
3
Akademija tehničkih strukovnih studija, Katarine Ambrozić 3, 11000 Beograd, Srbija
*Autor za korespondenciju: Ivana Adamov, E-mail: ivana.adamov@pharmacy.bg.ac.rs
Kratak sadržaj
Uvođenje tehnologije 3D štampe u oblasti farmacije uslovilo je razvoj fundamentalnih
promena, pri čemu serijska proizvodnja velikih šarži pretenduje da bude zamenjena malim
serijama lekova prilagođenih prema specifičnim potrebama pacijenata. Cilj istraživanja bio je da
se formulišu i izrade dvoslojne tablete primenom tehnike digitalne obrade svetlosti (DLP).
Hidrohlortiazid (HHT, 5%, m/m) i varfarin-natrijum (WS, 5%, m/m) odabrani su kao model
lekovite supstance. Proces štampanja sproveden je u prisustvu 0,1% fotoinicijatora, pri
konstantnom masenom odnosu poli(etilen glikol)diakrilata i poli(etilen glikola) 400, 1:1, uz
dodatak 10% vode. Jednoslojne 3D tablete prečnika 8,00 mm i debljine 1,50 mm, koje sadrže
HHT, odnosno WS, kao i kombinovane dvoslojne 3D tablete, sa svakom od aktivnih supstanci u
posebnom sloju, uspešno su odštampane. Prilikom ispitivanja brzine rastvaranja lekovite
supstance iz jednoslojnih tableta, došlo je do trenutnog (81,47±1,47%, nakon 45 min), ali
nepotpunog oslobađanja WS, i produženog i potpunog oslobađanja HHT (98,17±3,11%, nakon 8
h), dok je iz kombinovanih tableta zapaženo znatno sporije i nepotpuno oslobađanje obe lekovite
supstance. Potvrđeno je odsustvo interakcija i prisustvo slojevite strukture. DLP tehnika pruža
mogućnost jednostavne i brze izrade kombinovanih tableta, pri čemu je dalja optimizacija
formulacionih faktora neophodna u cilju postizanja potpunog oslobađanja lekovite supstance.
Ključne reči:
DLP tehnika, hidrohlortiazid, varfarin-natrijum,
kombinovane 3D tablete, personalizovana medicina
688